NECC
trustee files compensation plan for 2012 meningitis outbreak victims
Send a link to a friend
[December 04, 2014]
(Reuters) - The trustee overseeing
the bankruptcy of a Massachusetts pharmacy linked to a 2012 meningitis
outbreak that killed 64 people, filed a plan that would set aside at
least $135 million to compensate victims and their families.
|
The plan was filed after a federal bankruptcy court in July approved
a deal to settle scores of lawsuits against New England Compounding
Center (NECC).
NECC shut down in October 2012 after authorities linked it to the
worst outbreak of fungal meningitis in U.S. history due to drugs it
shipped to health providers across the country. The company filed
for bankruptcy two months later.
Owners of NECC, which produced a tainted steroid that sickened more
than 700 people in 20 states, have already contributed nearly $50
million to the NECC estate for eventual distribution and are
expected to contribute additional sums through tax refunds and the
sale of a related business.
Other third parties, including NECC's insurers and certain clinics
and health care providers that administered the tainted drugs, are
expected to contribute $56.8 million.
"The filing of this plan marks a crucial step in this tragic saga to
provide much needed financial relief to the victims and their
families. When NECC entered bankruptcy, many people doubted that the
victims would ever receive compensation through the bankruptcy
process," said David Molton, a lawyer for NECC's creditors'
committee.
If the plan is confirmed by U.S. Bankruptcy Court Judge Henry Boroff,
the contributing parties will receive releases from NECC-related
liability. The plan is expected to be confirmed at a hearing to be
held in early spring.
[to top of second column] |
A pharmacist who worked for NECC pleaded not guilty in September to
the first criminal charges filed in the case.
(Reporting by Supriya Kurane in Bengaluru; Editing by Gopakumar
Warrier)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|